The Duchenne muscular dystrophy drug developer's initial public offering could prove an exit ramp for Roche and Merck & Co.

US-based drug delivery platform developer Entrada Therapeutics has filed for an initial public offering (IPO) on the Nasdaq Global Market, marking a potential exit for pharmaceutical firms Merck & Co and Roche.

Entrada has developed endosomal escape vehicle (EEV) technology that is designed to help medication reach inside both large and small cells to treat genetic diseases.

Proceeds from the IPO will be used to advance its leading therapeutic candidate, the Duchenne muscular dystrophy-targeted ENTR-601-44, into clinical trials, advance…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn